Research programme: neuroprotective therapies - Magnolia Neurosciences
Latest Information Update: 28 Sep 2022
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Magnolia Neurosciences; University of Texas M. D. Anderson Cancer Center
- Class Antidementias; Antiparkinsonians; Neuroprotectants
- Mechanism of Action Cell death inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 27 Aug 2018 Magnolia Neurosciences plans a phase I trial for Neurodegenerative disorders in second half of 2019
- 22 Aug 2018 Preclinical trials in Neurodegenerative disorders in USA (unspecified route)